Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 114 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Doumas, Michael [Clear All Filters]
Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension..
J Clin Hypertens (Greenwich). 20(1), 65-68.
(2018). Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease..
Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
(2018). Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs..
Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
(2018). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). What is the role of statins in the elderly population?.
Expert Rev Clin Pharmacol. 11(4), 329-331.
(2018). Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?.
J Clin Hypertens (Greenwich). 19(12), 1336-1338.
(2017). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study..
Am J Med. 130(12), 1465.e27-1465.e39.
(2017).
(2017). The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins..
Curr Pharm Des. 23(10), 1477-1483.
(2017). Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis..
J Hypertens. 35(9), 1750-1757.
(2017). The effect of SGLT2 inhibitors on cardiovascular events and renal function..
Expert Rev Clin Pharmacol. 10(11), 1251-1261.
(2017). Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study..
Am J Nephrol. 45(2), 136-145.
(2017). Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension..
Am J Cardiol. 120(9), 1568-1571.
(2017). Left ventricular hypertrophy in athletes and hypertensive patients..
J Clin Hypertens (Greenwich). 19(4), 413-417.
(2017). Liraglutide and Renal Outcomes in Type 2 Diabetes..
N Engl J Med. 377(22), 2196.
(2017). Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun..
Curr Pharm Des. 23(10), 1540-1550.
(2017). Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?.
J Hypertens. 35(5), 950-952.
(2017). Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes..
N Engl J Med. 377(25), 2502.
(2017). Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?.
Curr Treat Options Cardiovasc Med. 19(5), 39.
(2017). SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature..
Curr Pharm Des. 23(10), 1510-1521.
(2017). Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?.
J Neurol Neurosurg Psychiatry. 88(3), 249-253.
(2017). Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters..
JAMA Intern Med. 177(9), 1393.
(2017).